Jinzhuang Liao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jinzhuang Liao has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Ruirui Wang
Department of Radiology, The Third Xiangya Hospital of Central South University, Tongzipo Road 138, Changsha, Hunan, 410013, China
5 shared publicationsPengfei Guo
Department of Radiology, The Third Xiangya Hospital of Central South University, Tongzipo Road 138, Changsha, Hunan, 410013, China
4 shared publications- Wei Li
Department of Radiology, the Third Xiangya Hospital of Central South University, Changsha, People’s Republic of China
4 shared publications Shuangze Han
Department of Radiology, The Third Xiangya Hospital of Central South University, Tongzipo Road 138, Changsha, Hunan, 410013, China
3 shared publicationsMing Yi
Department of Radiology, The Third Xiangya Hospital of Central South University, Tongzipo Road 138, Changsha, Hunan, 410013, China
2 shared publicationsShiming Tan
Department of Radiology, The Third Xiangya Hospital of Central South University, Changsha, China
2 shared publications
Latest Publications
- 19 March 2026
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 33 (6) , 673-684
Gracillin overcomes osimertinib resistance in NSCLC via dual inhibition of EGFR and Mcl-1
The advent of molecularly targeted therapies has revolutionized the clinical management of non-small cell lung cancer (NSCLC), substantially expanding therapeutic options. Nevertheless, significant clinical challenges persist, including acquired resistance, treatment-related toxicities, and economic burdens, underscoring the need for novel therapeutic strategies. In this study, we identified a promising epidermal growth factor receptor (EGFR)-targeting natural product, Gracillin. Unlike osimertinib's selective profile, Gracillin possesses broad-spectrum efficacy against both EGFR-mutant (including Ex19del, L858R, and T790M variants) and wild-type (WT) NSCLC. Mechanistically, Gracillin-mediated EGFR inhibition suppresses Akt signaling, leading to GSK3β-dependent phosphorylation of Mcl-1 at Ser159. This post-translational modification promotes β-TRCP-mediated K48-linked polyubiquitination and degradation of Mcl-1, thereby reducing its protein levels and subsequently inducing apoptosis. In vitro, Gracillin reduced cell viability by up to 90% (IC₅₀ ≈ 1.4-2.78 µM) in both EGFR-mutant and WT NSCLC cell lines. Notably, in vivo studies corroborated these findings, with Gracillin demonstrating significant tumor growth inhibition of up to 60% in both osimertinib-sensitive and -resistant NSCLC models. The compound's unique ability to target diverse EGFR genotypes while overcoming TKI resistance suggests its potential as a therapeutic agent with a strong rationale for further clinical development.
- 19 March 2026
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 33 (6) , 673-684
Gracillin overcomes osimertinib resistance in NSCLC via dual inhibition of EGFR and Mcl-1
The advent of molecularly targeted therapies has revolutionized the clinical management of non-small cell lung cancer (NSCLC), substantially expanding therapeutic options. Nevertheless, significant clinical challenges persist, including acquired resistance, treatment-related toxicities, and economic burdens, underscoring the need for novel therapeutic strategies. In this study, we identified a promising epidermal growth factor receptor (EGFR)-targeting natural product, Gracillin. Unlike osimertinib's selective profile, Gracillin possesses broad-spectrum efficacy against both EGFR-mutant (including Ex19del, L858R, and T790M variants) and wild-type (WT) NSCLC. Mechanistically, Gracillin-mediated EGFR inhibition suppresses Akt signaling, leading to GSK3β-dependent phosphorylation of Mcl-1 at Ser159. This post-translational modification promotes β-TRCP-mediated K48-linked polyubiquitination and degradation of Mcl-1, thereby reducing its protein levels and subsequently inducing apoptosis. In vitro, Gracillin reduced cell viability by up to 90% (IC₅₀ ≈ 1.4-2.78 µM) in both EGFR-mutant and WT NSCLC cell lines. Notably, in vivo studies corroborated these findings, with Gracillin demonstrating significant tumor growth inhibition of up to 60% in both osimertinib-sensitive and -resistant NSCLC models. The compound's unique ability to target diverse EGFR genotypes while overcoming TKI resistance suggests its potential as a therapeutic agent with a strong rationale for further clinical development.
- 2 October 2025
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 32 (12) , 1356-1369
Demethoxycurcumin suppresses HK2-mediated glycolysis by targeting PTEN/Akt signaling
Aerobic glycolysis is a hallmark of tumor cells, with the expression of glycolytic enzymes often being upregulated in many cancers, leading to enhanced metabolic activity. Among the key rate-limiting enzymes in this process, Hexokinase 2 (HK2) plays a crucial role in sustaining the biological activities of human cancers. Therefore, HK2 is considered a potential therapeutic target, although effective targeted drugs for oral squamous cell carcinoma (OSCC) treatment are currently lacking. To confirm potent anti-tumor agents that inhibit HK2 expression, we screened a library of 639 natural products and discovered that Demethoxycurcumin (Deme) was the most effective anti-tumor agent via inhibiting HK2-mediated glycolysis in OSCC cells, inducing intrinsic apoptosis. Mechanistically, Deme enhanced the interaction between USP13 and PTEN, leading to the stabilization of PTEN and consequent downregulation of HK2 via the PTEN/Akt/HK2 pathway. Notably, HK2 overexpression reversed the inhibitory effect of Deme on OSCC cells. Furthermore, at the tumor-inhibitory dose, Deme showed no effect on non-tumor HaCat cells. In vivo, Deme significantly suppressed tumor growth without apparent toxicity to vital organs. Together, these data suggest that Deme is a promising and safe anti-tumor compound that downregulates HK2 expression, providing a potential therapeutic strategy for OSCC treatment.
- 2 October 2025
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 32 (12) , 1356-1369
Demethoxycurcumin suppresses HK2-mediated glycolysis by targeting PTEN/Akt signaling
Aerobic glycolysis is a hallmark of tumor cells, with the expression of glycolytic enzymes often being upregulated in many cancers, leading to enhanced metabolic activity. Among the key rate-limiting enzymes in this process, Hexokinase 2 (HK2) plays a crucial role in sustaining the biological activities of human cancers. Therefore, HK2 is considered a potential therapeutic target, although effective targeted drugs for oral squamous cell carcinoma (OSCC) treatment are currently lacking. To confirm potent anti-tumor agents that inhibit HK2 expression, we screened a library of 639 natural products and discovered that Demethoxycurcumin (Deme) was the most effective anti-tumor agent via inhibiting HK2-mediated glycolysis in OSCC cells, inducing intrinsic apoptosis. Mechanistically, Deme enhanced the interaction between USP13 and PTEN, leading to the stabilization of PTEN and consequent downregulation of HK2 via the PTEN/Akt/HK2 pathway. Notably, HK2 overexpression reversed the inhibitory effect of Deme on OSCC cells. Furthermore, at the tumor-inhibitory dose, Deme showed no effect on non-tumor HaCat cells. In vivo, Deme significantly suppressed tumor growth without apparent toxicity to vital organs. Together, these data suggest that Deme is a promising and safe anti-tumor compound that downregulates HK2 expression, providing a potential therapeutic strategy for OSCC treatment.
- Open Access
- 7 April 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-15
E3 ligase Skp2-mediated stabilization of survivin contributes to radioresistance
Oral squamous cell carcinoma (OSCC) is a frequently occurring neck and head malignancy. Therapies for OSCC are improving, but radiotherapy resistance remains a major clinical challenge. Here, we found that the S-phase kinase-associated protein 2 (Skp2) is overexpressed in OSCC cells and tissues. Knockdown of Skp2 significantly increased the radiotherapy sensitivity of OSCC cells. Further potential mechanisms suggest that Skp2-deficient restoration of radiotherapy sensitivity in OSCC cells may induce intrinsic apoptosis through inhibition of the Akt/Wee1/CDK1 axis, which inhibits Survivin phosphorylation and promotes its ubiquitination and degradation by FBXL7. Clinicopathologic histological analysis showed that Skp2 was positively correlated with the expression of p-Akt and Survivin in OSCC tissues. Furthermore, knockdown or inhibition of Skp2 overcame the radiotherapy resistance of OSCC cells. In conclusion, our study demonstrated that targeting the Skp2-Survivin axis could serve as an attractive and promising potential therapeutic target for radiotherapy sensitization in OSCC.
- 7 April 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-15
Open AccessE3 ligase Skp2-mediated stabilization of survivin contributes to radioresistance
Oral squamous cell carcinoma (OSCC) is a frequently occurring neck and head malignancy. Therapies for OSCC are improving, but radiotherapy resistance remains a major clinical challenge. Here, we found that the S-phase kinase-associated protein 2 (Skp2) is overexpressed in OSCC cells and tissues. Knockdown of Skp2 significantly increased the radiotherapy sensitivity of OSCC cells. Further potential mechanisms suggest that Skp2-deficient restoration of radiotherapy sensitivity in OSCC cells may induce intrinsic apoptosis through inhibition of the Akt/Wee1/CDK1 axis, which inhibits Survivin phosphorylation and promotes its ubiquitination and degradation by FBXL7. Clinicopathologic histological analysis showed that Skp2 was positively correlated with the expression of p-Akt and Survivin in OSCC tissues. Furthermore, knockdown or inhibition of Skp2 overcame the radiotherapy resistance of OSCC cells. In conclusion, our study demonstrated that targeting the Skp2-Survivin axis could serve as an attractive and promising potential therapeutic target for radiotherapy sensitization in OSCC.
- Open Access
- 28 October 2024
- Published by Springer Nature in Cell Death Discovery
- Vol. 10 (1) , 1-16
Xanthohumol overcomes osimertinib resistance via governing ubiquitination-modulated Ets-1 turnover
Non-small cell lung cancer (NSCLC) is a prevalent and fatal malignancy with a significant global impact. Recent advancements have introduced targeted therapies like tyrosine kinase inhibitors (TKIs) such as osimertinib, which have improved patient outcomes, particularly in those with EGFR mutations. Despite these advancements, acquired resistance to TKIs remains a significant challenge. Hence, one of the current research priorities is understanding the resistance mechanisms and identifying new therapeutic targets to improve therapeutic efficacy. Herein, we identified high expression of c-Met in osimertinib-resistant NSCLC cells, and depletion of c-Met significantly inhibited the proliferation of osimertinib-resistant cells and prolonged survival in mice, suggesting c-Met as an attractive therapeutic target. To identify effective anti-tumor agents targeting c-Met, we screened a compound library containing 641 natural products and found that only xanthohumol exhibited potent inhibitory effects against osimertinib-resistant NSCLC cells. Moreover, combination treatment with xanthohumol and osimertinib sensitized osimertinib-resistant NSCLC cells to osimertinib both in vitro and in vivo. Mechanistically, xanthohumol disrupted the interaction between USP9X and Ets-1, and inhibited the phosphorylation of Ets-1 at Thr38, promoting its degradation, thereby targeting the Ets-1/c-Met signaling axis and inducing intrinsic apoptosis in osimertinib-resistant NSCLC cells. Overall, the research highlights the critical role of targeting c-Met to address osimertinib resistance in NSCLC. By demonstrating the efficacy of xanthohumol in overcoming resistance and enhancing therapeutic outcomes, this study provides valuable insights and potential new strategies for improving the clinical management of NSCLC.
- 28 October 2024
- Published by Springer Nature in Cell Death Discovery
- Vol. 10 (1) , 1-16
Open AccessXanthohumol overcomes osimertinib resistance via governing ubiquitination-modulated Ets-1 turnover
Non-small cell lung cancer (NSCLC) is a prevalent and fatal malignancy with a significant global impact. Recent advancements have introduced targeted therapies like tyrosine kinase inhibitors (TKIs) such as osimertinib, which have improved patient outcomes, particularly in those with EGFR mutations. Despite these advancements, acquired resistance to TKIs remains a significant challenge. Hence, one of the current research priorities is understanding the resistance mechanisms and identifying new therapeutic targets to improve therapeutic efficacy. Herein, we identified high expression of c-Met in osimertinib-resistant NSCLC cells, and depletion of c-Met significantly inhibited the proliferation of osimertinib-resistant cells and prolonged survival in mice, suggesting c-Met as an attractive therapeutic target. To identify effective anti-tumor agents targeting c-Met, we screened a compound library containing 641 natural products and found that only xanthohumol exhibited potent inhibitory effects against osimertinib-resistant NSCLC cells. Moreover, combination treatment with xanthohumol and osimertinib sensitized osimertinib-resistant NSCLC cells to osimertinib both in vitro and in vivo. Mechanistically, xanthohumol disrupted the interaction between USP9X and Ets-1, and inhibited the phosphorylation of Ets-1 at Thr38, promoting its degradation, thereby targeting the Ets-1/c-Met signaling axis and inducing intrinsic apoptosis in osimertinib-resistant NSCLC cells. Overall, the research highlights the critical role of targeting c-Met to address osimertinib resistance in NSCLC. By demonstrating the efficacy of xanthohumol in overcoming resistance and enhancing therapeutic outcomes, this study provides valuable insights and potential new strategies for improving the clinical management of NSCLC.
- 1 January 2024
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- Vol. 52 (03) , 865-884
Xanthohumol Promotes Skp2 Ubiquitination Leading to the Inhibition of Glycolysis and Tumorigenesis in Ovarian Cancer
Ovarian cancer is a common, highly lethal tumor. Herein, we reported that S-phase kinase-associated protein 2 (Skp2) is essential for the growth and aerobic glycolysis of ovarian cancer cells. Skp2 was upregulated in ovarian cancer tissues and associated with poor clinical outcomes. Using a customized natural product library screening, we found that xanthohumol inhibited aerobic glycolysis and cell viability of ovarian cancer cells. Xanthohumol facilitated the interaction between E3 ligase Cdh1 and Skp2 and promoted the Ub-K48-linked polyubiquitination of Skp2 and degradation. Cdh1 depletion reversed xanthohumol-induced Skp2 downregulation, enhancing HK2 expression and glycolysis in ovarian cancer cells. Finally, a xenograft tumor model was employed to examine the antitumor efficacy of xanthohumol in vivo. Collectively, we discovered that xanthohumol promotes the binding between Skp2 and Cdh1 to suppress the Skp2/AKT/HK2 signal pathway and exhibits potential antitumor activity for ovarian cancer cells.
- 1 January 2024
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- Vol. 52 (03) , 865-884
Xanthohumol Promotes Skp2 Ubiquitination Leading to the Inhibition of Glycolysis and Tumorigenesis in Ovarian Cancer
Ovarian cancer is a common, highly lethal tumor. Herein, we reported that S-phase kinase-associated protein 2 (Skp2) is essential for the growth and aerobic glycolysis of ovarian cancer cells. Skp2 was upregulated in ovarian cancer tissues and associated with poor clinical outcomes. Using a customized natural product library screening, we found that xanthohumol inhibited aerobic glycolysis and cell viability of ovarian cancer cells. Xanthohumol facilitated the interaction between E3 ligase Cdh1 and Skp2 and promoted the Ub-K48-linked polyubiquitination of Skp2 and degradation. Cdh1 depletion reversed xanthohumol-induced Skp2 downregulation, enhancing HK2 expression and glycolysis in ovarian cancer cells. Finally, a xenograft tumor model was employed to examine the antitumor efficacy of xanthohumol in vivo. Collectively, we discovered that xanthohumol promotes the binding between Skp2 and Cdh1 to suppress the Skp2/AKT/HK2 signal pathway and exhibits potential antitumor activity for ovarian cancer cells.
- Open Access
- 2 October 2023
- Published by Springer Nature in Cell Death Discovery
- Vol. 9 (1) , 1-13
Gastrodin overcomes chemoresistance via inhibiting Skp2-mediated glycolysis
Aerobic glycolysis, a typical phenotype in human tumors, is associated with tumor progression and chemotherapy resistance. The present study demonstrated that cisplatin-resistant oral squamous cell carcinoma (OSCC) cells exerted a stronger glycolysis ability, which was associated with hexokinase 2 (HK2) overexpression. Additionally, the tumor growth of OSCC cells was delayed in vivo and the glycolysis was notably decreased following HK2 knockdown. The natural compound screening revealed that gastrodin could be an effective candidate for OSCC therapy since it inhibited HK2-mediated glucose metabolism and promoted endogenous OSCC cell apoptosis. Furthermore, gastrodin could bind to protein kinase B (Akt) and suppress its activity, thus downregulating HK2 at the transcriptional level. Additionally, S-phase kinase-associated protein 2 (Skp2) was highly expressed in OSCC cells, while K63-linked ubiquitination of Akt was inhibited in Skp2-depleted cisplatin-resistant OSCC cells. Gastrodin could also inhibit the cisplatin resistance of OSCC cells in vivo, particularly when combined with the Skp2 inhibitor, SZL P1-41. Overall, the aforementioned finding suggested that targeting the Skp2-Akt axis could be a potential therapeutic strategy for treating OSCC and overcoming chemoresistance.
- 2 October 2023
- Published by Springer Nature in Cell Death Discovery
- Vol. 9 (1) , 1-13
Open AccessGastrodin overcomes chemoresistance via inhibiting Skp2-mediated glycolysis
Aerobic glycolysis, a typical phenotype in human tumors, is associated with tumor progression and chemotherapy resistance. The present study demonstrated that cisplatin-resistant oral squamous cell carcinoma (OSCC) cells exerted a stronger glycolysis ability, which was associated with hexokinase 2 (HK2) overexpression. Additionally, the tumor growth of OSCC cells was delayed in vivo and the glycolysis was notably decreased following HK2 knockdown. The natural compound screening revealed that gastrodin could be an effective candidate for OSCC therapy since it inhibited HK2-mediated glucose metabolism and promoted endogenous OSCC cell apoptosis. Furthermore, gastrodin could bind to protein kinase B (Akt) and suppress its activity, thus downregulating HK2 at the transcriptional level. Additionally, S-phase kinase-associated protein 2 (Skp2) was highly expressed in OSCC cells, while K63-linked ubiquitination of Akt was inhibited in Skp2-depleted cisplatin-resistant OSCC cells. Gastrodin could also inhibit the cisplatin resistance of OSCC cells in vivo, particularly when combined with the Skp2 inhibitor, SZL P1-41. Overall, the aforementioned finding suggested that targeting the Skp2-Akt axis could be a potential therapeutic strategy for treating OSCC and overcoming chemoresistance.
- 1 January 2023
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- Vol. 51 (08) , 2221-2241
Isoliquiritigenin Inhibits Oral Squamous Cell Carcinoma and Overcomes Chemoresistance by Destruction of Survivin
The oncoprotein survivin plays a pivotal role in controlling cell division and preventing apoptosis by inhibiting caspase activation. Its significant contribution to tumorigenesis and therapeutic resistance has been well established. Isoliquiritigenin (ISL), a natural compound, has been recognized for its powerful inhibitory effects against various tumors. However, whether ISL exerts regulatory effects on survivin and its underlying mechanism in oral squamous cell carcinoma (OSCC) remains unclear. Here, we found that ISL inhibited the viability and colony formation of OSCC, and promoted their apoptosis. The immunoblotting data showed that ISL treatment significantly decreased survivin expression. Mechanistically, ISL suppressed survivin phosphorylation on Thr34 by deregulating Akt-Wee1-CDK1 signaling, which facilitated survivin for ubiquitination degradation. ISL inhibited CAL27 tumor growth and decreased p-Akt and survivin expression in vivo. Meanwhile, survivin overexpression caused cisplatin resistance of OSCC cells. ISL alone or combined with cisplatin overcame chemoresistance in OSCC cells. Overall, our results revealed that ISL exerted potent inhibitory effects via inducing Akt-dependent survivin ubiquitination in OSCC cells.
- 1 January 2023
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- Vol. 51 (08) , 2221-2241
Isoliquiritigenin Inhibits Oral Squamous Cell Carcinoma and Overcomes Chemoresistance by Destruction of Survivin
The oncoprotein survivin plays a pivotal role in controlling cell division and preventing apoptosis by inhibiting caspase activation. Its significant contribution to tumorigenesis and therapeutic resistance has been well established. Isoliquiritigenin (ISL), a natural compound, has been recognized for its powerful inhibitory effects against various tumors. However, whether ISL exerts regulatory effects on survivin and its underlying mechanism in oral squamous cell carcinoma (OSCC) remains unclear. Here, we found that ISL inhibited the viability and colony formation of OSCC, and promoted their apoptosis. The immunoblotting data showed that ISL treatment significantly decreased survivin expression. Mechanistically, ISL suppressed survivin phosphorylation on Thr34 by deregulating Akt-Wee1-CDK1 signaling, which facilitated survivin for ubiquitination degradation. ISL inhibited CAL27 tumor growth and decreased p-Akt and survivin expression in vivo. Meanwhile, survivin overexpression caused cisplatin resistance of OSCC cells. ISL alone or combined with cisplatin overcame chemoresistance in OSCC cells. Overall, our results revealed that ISL exerted potent inhibitory effects via inducing Akt-dependent survivin ubiquitination in OSCC cells.